Mostrar el registro sencillo del ítem

dc.contributor.authorRodríguez Sojo, María Jesús 
dc.contributor.authorRuiz Malagón, Antonio Jesús 
dc.contributor.authorRodríguez Cabezas, María Elena 
dc.contributor.authorGálvez Peralta, Julio Juan 
dc.contributor.authorRodríguez Nogales, Alba 
dc.date.accessioned2021-04-30T08:38:54Z
dc.date.available2021-04-30T08:38:54Z
dc.date.issued2021-03-21
dc.identifier.citationRodríguez-Sojo, M.J.; Ruiz-Malagón, A.J.; Rodríguez-Cabezas, M.E.; Gálvez, J.; Rodríguez-Nogales, A. Limosilactobacillus fermentum CECT5716: Mechanisms and Therapeutic Insights. Nutrients 2021, 13, 1016. [https://doi.org/10.3390/nu13031016]es_ES
dc.identifier.urihttp://hdl.handle.net/10481/68227
dc.descriptionThis work was supported by the Junta de Andalucía (CTS 164) and Instituto de Salud Carlos III (PI19/01058) with funds from the European Union.es_ES
dc.descriptionM.J. Rodríguez-Sojo is a predoctoral fellow from University of Granada (“Programa de Doctorado en Biomedicina”); A.J. Ruiz-Malagón is a predoctoral fellow from Formación de Profesorado Universitario Program (“Programa de Doctorado en Medicina Clínica y Salud Pública”), and A. Rodríguez-Nogales is a postdoctoral fellow of Instituto de Salud Carlos III (Miguel Servet Program).es_ES
dc.description.abstractProbiotics microorganisms exert their health-associated activities through some of the following general actions: competitive exclusion, enhancement of intestinal barrier function, production of bacteriocins, improvement of altered microbiota, and modulation of the immune response. Among them, Limosilactobacillus fermentum CECT5716 has become one of the most promising probiotics and it has been described to possess potential beneficial effects on inflammatory processes and immunological alterations. Different studies, preclinical and clinical trials, have evidenced its anti-inflammatory and immunomodulatory properties and elucidated the precise mechanisms of action involved in its beneficial effects. Therefore, the aim of this review is to provide an updated overview of the effect on host health, mechanisms, and future therapeutic approaches.es_ES
dc.description.sponsorshipJunta de Andalucia CTS 164es_ES
dc.description.sponsorshipInstituto de Salud Carlos III European Commission PI19/01058es_ES
dc.description.sponsorshipEuropean Commissiones_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsAtribución 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectProbiotices_ES
dc.subjectLimosilactobacillus fermentum CECT5716es_ES
dc.subjectImmunomodulationes_ES
dc.subjectDysbiosises_ES
dc.subjectMechanism of actiones_ES
dc.subjectGastrointestinal diseaseses_ES
dc.subjectMicrobiotaes_ES
dc.titleLimosilactobacillus fermentum CECT5716: Mechanisms and Therapeutic Insightses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.doi10.3390/nu13031016
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES


Ficheros en el ítem

[PDF]

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 3.0 España
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 3.0 España